Focus Partners Wealth’s Roivant Sciences ROIV Stock Holding History

Focus Partners Wealth’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,935	Closed	-$386K	–	2941
2026 Q1	$386K	Buy	+13,935	New	+$358K	﹤0.01%	2047

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Focus Partners Wealth's ROIV Position: Q2 2026 in Review

Focus Partners Wealth sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 13,935 shares — an estimated $386K sold.

Focus Partners Wealth first reported a position in ROIV in Q1 2026 and held it in 1 quarter. The position peaked at $386K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Focus Partners Wealth reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Focus Partners Wealth sold 13,935 Roivant Sciences shares in Q2 2026, an estimated $386K.
Focus Partners Wealth first reported a position in Roivant Sciences in Q1 2026 and held it in 1 quarter.
Focus Partners Wealth's Roivant Sciences position peaked at $386K in Q1 2026.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.